Lv1
90 积分 2023-07-14 加入
MSR60 Modeling Challenges for Cancer Drugs With Unprecedented Outcomes: Lorlatinib in the First Line Setting of ALK+ aNSCLS As a Case Study
2天前
求助中
Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases
17天前
已完结
Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy
17天前
已完结
Atypical EGFR Mutations Show Heterogeneity
1个月前
已完结
The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies
1个月前
已完结
Metastatic sites and survival in lung cancer
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics
3个月前
已完结
Synergy of advanced machine learning and deep neural networks with consensus molecular docking for virtual screening of anaplastic lymphoma kinase inhibitors
3个月前
已完结
Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study
3个月前
已完结
皖公网安备34019202002308
